MX2022015742A - Formas farmaceuticas osmoticas que comprenden deutetrabenazina y metodos de uso de las mismas. - Google Patents

Formas farmaceuticas osmoticas que comprenden deutetrabenazina y metodos de uso de las mismas.

Info

Publication number
MX2022015742A
MX2022015742A MX2022015742A MX2022015742A MX2022015742A MX 2022015742 A MX2022015742 A MX 2022015742A MX 2022015742 A MX2022015742 A MX 2022015742A MX 2022015742 A MX2022015742 A MX 2022015742A MX 2022015742 A MX2022015742 A MX 2022015742A
Authority
MX
Mexico
Prior art keywords
dosage forms
deutetrabenazine
osmotic dosage
methods
treatment
Prior art date
Application number
MX2022015742A
Other languages
English (en)
Inventor
Parag Shah
Mayank Joshi
Soumen Pattanayek
Divyang Patel
Sandeep Pandita
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of MX2022015742A publication Critical patent/MX2022015742A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

Se proporcionan en el presente documento formas farmacéuticas osmóticas que contienen deutetrabenazina para su uso en el tratamiento de, por ejemplo, trastornos de movimiento hipercinéticos. Cuando se administran por vía oral a un sujeto diariamente una vez al día, las formas farmacéuticas proporcionan un perfil farmacocinético favorable para el principio activo indicando una eficacia del tratamiento durante un periodo extendido de tiempo.
MX2022015742A 2020-06-10 2021-06-10 Formas farmaceuticas osmoticas que comprenden deutetrabenazina y metodos de uso de las mismas. MX2022015742A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063037369P 2020-06-10 2020-06-10
US202063037953P 2020-06-11 2020-06-11
US202063044451P 2020-06-26 2020-06-26
PCT/US2021/036778 WO2021252741A1 (en) 2020-06-10 2021-06-10 Osmotic dosage forms comprising deutetrabenazine and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022015742A true MX2022015742A (es) 2023-01-19

Family

ID=78826343

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015742A MX2022015742A (es) 2020-06-10 2021-06-10 Formas farmaceuticas osmoticas que comprenden deutetrabenazina y metodos de uso de las mismas.

Country Status (20)

Country Link
US (2) US11311488B2 (es)
EP (2) EP4153136B1 (es)
JP (2) JP7419571B2 (es)
KR (2) KR102638424B1 (es)
CN (1) CN115916154A (es)
AU (2) AU2021288087B2 (es)
BR (1) BR112022025185B1 (es)
CA (1) CA3186425A1 (es)
CL (1) CL2022003512A1 (es)
DK (1) DK4153136T3 (es)
FI (1) FI4153136T3 (es)
HR (1) HRP20240303T1 (es)
IL (1) IL298629A (es)
LT (1) LT4153136T (es)
MX (1) MX2022015742A (es)
PE (1) PE20230852A1 (es)
PT (1) PT4153136T (es)
RS (1) RS65328B1 (es)
TW (1) TW202214246A (es)
WO (1) WO2021252741A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023240186A1 (en) * 2022-06-08 2023-12-14 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US20030161882A1 (en) * 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
US20070031496A1 (en) * 2005-08-04 2007-02-08 Edgren David E Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties
US20120208773A1 (en) * 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
ES2425623T3 (es) 2008-09-18 2013-10-16 Auspex Pharmaceuticals, Inc. Inhibidores benzoquinolínicos de transportador vesicular de monoaminas 2
JP2013501810A (ja) * 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
CN111728971A (zh) * 2012-09-18 2020-10-02 奥斯拜客斯制药有限公司 D6-四苯喹嗪固体口服剂型、化合物、及其药物组合物、制备及治疗方法
US10479787B2 (en) * 2016-04-22 2019-11-19 Lupin Limited Process for preparation of tetrabenazine and deutetrabenazine
US20170312226A1 (en) * 2016-04-28 2017-11-02 Ascent Pharmaceuticals, Inc. Pharmaceutical dosage forms
US11813232B2 (en) * 2017-03-15 2023-11-14 Auspex Pharmaceuticals, Inc. Analogs of deutetrabenazine, their preparation and use
CA3104693A1 (en) * 2018-08-15 2020-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors

Also Published As

Publication number Publication date
AU2021288087B2 (en) 2023-03-30
PE20230852A1 (es) 2023-05-29
BR112022025185B1 (pt) 2023-10-24
PT4153136T (pt) 2024-03-22
TW202214246A (zh) 2022-04-16
US11311488B2 (en) 2022-04-26
WO2021252741A1 (en) 2021-12-16
JP2024058686A (ja) 2024-04-26
CN115916154A (zh) 2023-04-04
US20210386673A1 (en) 2021-12-16
JP7419571B2 (ja) 2024-01-22
AU2021288087A1 (en) 2023-01-19
US20230022862A1 (en) 2023-01-26
BR112022025185A2 (pt) 2022-12-27
CA3186425A1 (en) 2021-12-16
KR102638424B1 (ko) 2024-02-19
LT4153136T (lt) 2024-03-25
KR20240025706A (ko) 2024-02-27
CL2022003512A1 (es) 2023-07-28
FI4153136T3 (fi) 2024-03-19
RS65328B1 (sr) 2024-04-30
JP2023523092A (ja) 2023-06-01
EP4153136A1 (en) 2023-03-29
EP4364738A2 (en) 2024-05-08
IL298629A (en) 2023-01-01
AU2023204103A1 (en) 2023-07-13
KR20230016703A (ko) 2023-02-02
DK4153136T3 (da) 2024-03-25
HRP20240303T1 (hr) 2024-05-10
EP4153136B1 (en) 2024-01-10

Similar Documents

Publication Publication Date Title
ATE504288T1 (de) Oros-push-stick für die kontrollierte abgabe von wirkstoffen
MX2022006681A (es) Sistema de suministro transdermico de donepezilo.
NZ630166A (en) Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
JP2013505282A5 (es)
AR040722A1 (es) Formulaciones y formas de dosificacion para la administracion controlada de topiramato
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2021000376A (es) Composiciones tópicas para el alivio del dolor.
NZ605469A (en) Nalbuphine-based formulations and uses thereof
RU2011137131A (ru) Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
CO6771406A2 (es) Una composición combinada
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
NZ759173A (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
MX2022015742A (es) Formas farmaceuticas osmoticas que comprenden deutetrabenazina y metodos de uso de las mismas.
RU2007122391A (ru) S-миртазапин для лечения приливов
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
JP2011516544A5 (es)
AR046146A1 (es) Formulaciones farmaceuticas transdermicas para pulverizacion que comprenden un agente activo, un copolimero de vp/va y un vehiculo no acuoso
MX2013005482A (es) Composicion farmaceutica que contiene sales de citrato y bicarbonato, y su uso para el tratamiento de la cistinuria.
HRP20230735T1 (hr) Betahistin, ili njegova farmaceutski prihvatljiva sol, i inhibitor monoamin oksidaze, za uporabu u liječenju ili prevenciji jednog ili više simptoma vrtoglavice kod subjekta
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
HRP20211309T1 (hr) N,n-bis-2-merkaptoetil izoftalamid za liječenje parkinsonove bolesti
ES2572180T3 (es) Formulaciones de liberación controlada que comprenden unidad(es) discreta(s) sin recubrimiento y una matriz de liberación prolongada